In a breakthrough for malaria prevention, scientists have discovered how two newly developed monoclonal antibodies (mAbs) effectively neutralize the deadliest malaria parasite, Plasmodium falciparum. This advancement arrives at a crucial moment, as global efforts to combat malaria have slowed due to growing resistance to drugs, insecticides, and limited vaccination coverage.
Stalled Progress and Growing Resistance Demand Innovation
Despite decades of mosquito-control programs and antimalarial drugs, progress has plateaued. In many regions, mosquitoes have developed resistance to insecticides, and parasites are evolving to resist treatment. Vaccination efforts, though promising, have yet to achieve widespread immunization, particularly among children—the group most vulnerable to malaria.
U.S. Scientists Develop mAbs Targeting Malaria Parasite
An interdisciplinary team from the Vaccine Research Center (VRC) in Bethesda, Maryland—a division of the National Institute of Allergy and Infectious Diseases—engineered two potent mAbs: CIS43LS and L9LS. These antibodies bind with high specificity to separate regions on the circumsporozoite protein (PfCSP), a surface protein on the parasite’s sporozoite stage.
Their findings, published in Science Translational Medicine, offer new insight into malaria prevention and the future of antibody-based therapies.
A Disbanded Team Leaves Behind Groundbreaking Science
Although the VRC team has since disbanded amid funding uncertainties, their work continues to influence malaria research. The two antibodies they developed proved effective in preclinical murine models, demonstrating strong potential for human use without relying on the typical Fc receptor pathway.
How the Antibodies Work
The antibodies bind to the sporozoite form of Plasmodium falciparum—a stage early in the parasite’s lifecycle, before it reaches the liver. By blocking this entry point, the antibodies halt further development of the disease. Both CIS43LS and L9LS offered complete protection in mouse models, even without Fc receptor engagement, which is typically required for immune responses.
A Stronger Shield Than Traditional Approaches
According to lead researcher Dr. Neville K. Kisalu, monoclonal antibodies offer unique advantages: rapid protection after a single dose, broad applicability across age groups, and a high safety profile. Unlike vaccines, which require time to become effective and multiple doses to maintain protection, mAbs act quickly and are ready for deployment even in outbreak settings.
Real-World Urgency and Global Impact
Kisalu emphasized the need for expanded malaria interventions. “Malaria remains a huge public health challenge, especially in African countries,” he said. While WHO estimates place the annual death toll at 597,000, Kisalu’s team estimated it at nearly 700,000, citing different methodologies.
Currently, adults in endemic regions often carry parasites in their bloodstream without symptoms. These individuals serve as reservoirs, enabling the disease to spread via mosquito bites, particularly to children. Kisalu noted this stage offers a valuable window for intervention—before parasites reach the liver and cause severe illness.
Toward the Next Generation of Antibodies
As reported by medicalxpress, the research team also suggested ways to improve the antibodies. By increasing their binding affinity to target proteins, next-generation mAbs could become two-to-three times more potent. This would not only enhance their protective effect but also lower production and treatment costs.
A New Weapon in the Fight Against Malaria
In conclusion, while global malaria control has seen setbacks, monoclonal antibodies like CIS43LS and L9LS present a powerful new tool. As researchers look to optimize these therapies, they hold promise to transform the prevention landscape—providing fast, effective protection for people of all ages and helping to reverse the recent rise in cases.